Daily Bio News Summary — 2026-07-29: Q2 earnings drive biopharma headlines as FDA tightens reviews

Forty-three fresh articles cleared the 30-day filter today, drawn from all eleven sources in the rotation (BioSpace, Fierce Pharma, Fierce Biotech, STAT News, Endpoints News, FDA Newsroom, BioPharma Dive, MedCity News, Reuters Biopharma, Pharmaphorum, PR Newswire FDA). The category split was Therapeutics Development 15, Clinical Regulatory 15, Business & Strategy 10, Careers & Market 3 — heavily skewed toward late-July earnings reporting and FDA decision activity.

FDA activity clusters the regulatory headline

Five articles today trace FDA actions directly. Endpoints News reported that FDA reviewers concluded Replimune’s pivotal melanoma trial failed to demonstrate that its oncolytic immunotherapy RP1 works, ahead of an advisory committee meeting (Endpoints News, 2026-07-29). A separate Fierce Pharma piece covered two FDA manufacturing citations against Hengrui Pharmaceuticals and Elevar Therapeutics tied to their investigational liver-cancer combination (Fierce Pharma, 2026-07-28). On the approval side, FDA authorized Caristo Diagnostics’ CaRi-Heart coronary inflammation AI tool (PR Newswire FDA, 2026-07-29) and Viatris’s once-weekly contraceptive patch Gwyn Lo (PR Newswire FDA, 2026-07-29). CalciMedica announced FDA alignment on its Phase 2b Auxora trial in acute pancreatitis (PR Newswire FDA, 2026-07-29). Lupin received approval for its Diazepam Injection generic (PR Newswire FDA, 2026-07-28), and the FDA also published updated guidance for generics of weight-loss blockbusters (Endpoints News, 2026-07-29). Separately, an FDA staff statement reminded investors that re-evaluations of existing data don’t automatically produce new regulatory conclusions (Endpoints News, 2026-07-29).

Q2 earnings season dominates business coverage

Biogen was the day’s most-cited single name, with three articles touching its Q2 print. Reuters reported Biogen beat quarterly estimates driven by newer-product growth (Reuters Biopharma, 2026-07-29). Endpoints News separately covered Leqembi’s best quarter since launch and the underlying guidance raise (Endpoints News, 2026-07-29). BioSpace framed the same print as a strategic M&A signal — Biogen shifting toward bolt-on deals after its Apellis acquisition pushed revenue above expectations (BioSpace, 2026-07-29). Incyte executives projected Opzelura will cross $1B in 2026 sales (Fierce Pharma, 2026-07-29) and separately disclosed cutting an early-stage oncology candidate to refocus on next-gen programs (BioSpace, 2026-07-29). Teva’s leadership said its branded and biosimilar growth is offsetting generic price erosion (Fierce Pharma, 2026-07-29). Eli Lilly took the top spot on a new biopharma productivity ranking, ahead of AbbVie and Vertex (Fierce Biotech, 2026-07-28). MapLight Therapeutics shares dropped despite positive Phase 2 schizophrenia data, with investors focusing on the competitive profile against existing antipsychotics (BioPharma Dive, 2026-07-26). BioSpace’s weekly earnings recap covered Capricor and Replimune preparing for FDA adcomm meetings and Sarepta’s incoming CEO transition (BioSpace, 2026-07-29).

M&A and reverse mergers

Four reverse-merger / acquisition items landed today. Processa Pharmaceuticals acquired privately held Vidya Therapeutics, picking up an early-stage cutaneous T-cell lymphoma candidate positioned as a potential rival to BMS’s recently approved Hympavzi-class agent (Fierce Biotech, 2026-07-29). Caldera Therapeutics closed its reverse merger with the Synlogic shell, listing on Nasdaq to advance targeted oncology candidates (Fierce Biotech, 2026-07-29). Endpoints News reported two private biotechs signed reverse mergers to advance an I&I candidate and a BTK inhibitor (Endpoints News, 2026-07-29). Vertex paid AbCellera Biologics $28M upfront under a multi-target antibody discovery deal aimed at autoimmune T-cell engager programs (Fierce Biotech, 2026-07-29). Doctronic acquired pediatric telehealth provider Summer Health to expand into pediatric care (Endpoints News, 2026-07-29). Trace Biosciences took a strategic equity investment from Axogen to advance its nerve-repair pipeline (PR Newswire FDA, 2026-07-29). CG Life merged with AI branding firm The Considered+AI to broaden its biopharma AI capabilities (Fierce Pharma, 2026-07-29). Victory Square provided an update on its Hydreight subsidiary and broader healthcare portfolio post-acquisition (PR Newswire FDA, 2026-07-29).

Talc litigation: J&J proposes $5.5B

Johnson & Johnson proposed a $5.5B settlement to resolve roughly 76,000 lawsuits alleging its talc-based products caused ovarian cancer — the company’s largest talc-related deal to date (Endpoints News, 2026-07-29; Fierce Pharma, 2026-07-28).

GLP-1 expansion continues

Three articles today trace GLP-1 expansion beyond diabetes/obesity. Altimmune reported its GLP-1 agonist pemvidutide significantly reduced heavy drinking days in a mid-stage alcohol use disorder trial, supporting a metabolic-mechanism thesis for addiction (MedCity News, 2026-07-01). FlyteHealth achieved general availability of its digital obesity-care platform within the CMS Health Technology Ecosystem, broadening Medicare beneficiaries’ access to GLP-1-supported care (PR Newswire FDA, 2026-07-28). The FDA’s updated generics guidance for weight-loss blockbusters (Endpoints News, 2026-07-29) signals forthcoming biosimilar/generic competition for the current GLP-1 incumbents. Aqua Medical also treated the first U.S. patient in a type 2 diabetes feasibility study using its investigational steam-ablation catheter (PR Newswire FDA, 2026-07-28), and Nitinotes announced first study procedures at Orlando Health in its EASE IDE trial for endoscopic weight loss (PR Newswire FDA, 2026-07-28).

Manufacturing and regulatory mid-stream

CSL announced plans to begin clinical trials of a new immunoglobulin manufacturing process aimed at expanding supply for primary immunodeficiency patients (Reuters Biopharma, 2026-07-29). Kyverna Therapeutics tapped ElevateBio to manufacture commercial supply of its autoimmune CAR-T therapy, securing capacity ahead of a planned BLA filing (BioSpace, 2026-07-29). A federal judge denied Novo Nordisk’s motion to dismiss a securities class action over its 2024 CagriSema obesity-pipeline readout, allowing the case to proceed (Fierce Biotech, 2026-07-29). The UK Prescription Medicines Code of Practice Authority sanctioned a melatonin product manufacturer for misleading promotional claims (Fierce Pharma, 2026-07-29).

What this batch is NOT telling us

Today’s slate is short on AI-bio state-of-the-field news, no IPOs, no Phase 3 readouts (apart from MapLight’s mid-stage schizophrenia result), and no early-pipeline trial initiations in oncology. The sourcing skews heavily toward regulatory and earnings-side coverage; the “scientific frontier” voice is absent. STAT’s news file today also runs lighter than usual, with one pediatric-isolation policy piece and one PCOS-renaming health-equity piece but no clinical-research deep-dives.

Reading order for limited time

If only five items: Endpoints News on Replimune’s failed pivotal trial (regulatory inflection); Endpoints News on Leqembi’s best quarter and the Biogen guidance raise (commercial inflection); Fierce Pharma on J&J’s $5.5B talc proposal (litigation inflection); Fierce Biotech on Vertex’s $28M AbCellera TCE deal (M&A inflection); MedCity News on Altimmune’s GLP-1 alcohol use disorder data (mechanism-expansion inflection).

How to read the underlying articles

All 43 items today live in ~/my-repos/openbionews.com/src/content/news/. Each markdown file carries sourceUrl and sourceName frontmatter — click through to the original article for the full text. The frontmatter is deliberately minimal: title, 1-2 sentence description, pubDate, category, tags, companyId (where applicable), sourceUrl, sourceName. The site renders these on the homepage news list; click an item for the source-link out.

Today’s 43 items (in chronological order)

1. Prolonged hospital stays can leave children isolated (STAT News, 2026-07-29)
2. Biogen beats quarterly estimates (Reuters Biopharma, 2026-07-29) — biogen
3. CSL starts clinical trials for new immunoglobulin process (Reuters Biopharma, 2026-07-29)
4. Caristo Diagnostics CaRi-Heart FDA authorization (PR Newswire FDA, 2026-07-29)
5. KPM Analytics SiftAI FM HD Platform (PR Newswire FDA, 2026-07-29)
6. Victory Square update on Hydreight (PR Newswire FDA, 2026-07-29)
7. Trace Biosciences investment from Axogen (PR Newswire FDA, 2026-07-29)
8. CalciMedica FDA alignment on Auxora Phase 2b (PR Newswire FDA, 2026-07-29)
9. Viatris FDA approval for Gwyn Lo (PR Newswire FDA, 2026-07-29)
10. Incyte expects Opzelura to cross $1B (Fierce Pharma, 2026-07-29)
11. Teva’s innovation engine offsets generic pressures (Fierce Pharma, 2026-07-29)
12. CG Life joins forces with The Considered+AI (Fierce Pharma, 2026-07-29)
13. PMCPA sanctions melatonin drugmaker (Fierce Pharma, 2026-07-29)
14. Novo Nordisk fails to dismiss CagriSema lawsuit (Fierce Biotech, 2026-07-29) — novo-nordisk
15. Processa acquires Vidya (Fierce Biotech, 2026-07-29)
16. Caldera hits Nasdaq via Synlogic reverse merger (Fierce Biotech, 2026-07-29)
17. Vertex’s autoimmune TCE play $28M AbCellera (Fierce Biotech, 2026-07-29) — vertex-pharmaceuticals
18. Two biotechs reverse mergers for I&I drug, BTK inhibitor (Endpoints News, 2026-07-29)
19. Leqembi best quarter since launch (Endpoints News, 2026-07-29) — biogen
20. Doctronic buys Summer Health (Endpoints News, 2026-07-29)
21. FDA reminds investors re-evaluations don’t equal conclusions (Endpoints News, 2026-07-29)
22. J&J proposes $5.5B talc settlement (Endpoints News, 2026-07-29) — johnson-and-johnson
23. FDA staff say Replimune’s melanoma trial failed (Endpoints News, 2026-07-29)
24. FDA offers updated guidance for generics of weight loss blockbusters (Endpoints News, 2026-07-29)
25. Biogen shifts M&A strategy post-Apellis (BioSpace, 2026-07-29) — apellis-pharmaceuticals
26. Kyverna taps ElevateBio for CAR-T supply (BioSpace, 2026-07-29)
27. Oncology experience needed for oncology jobs? (BioSpace, 2026-07-29)
28. 7 companies hiring in New York now (BioSpace, 2026-07-29)
29. Incyte cuts early-stage cancer drug (BioSpace, 2026-07-29)
30. Capricor / Replimune adcomms, Q2 earnings (BioSpace, 2026-07-29)
31. Biotechs bring big launches into Q2 earnings (BioSpace, 2026-07-29)
32. After PCOS became PMOS, new awareness (STAT News, 2026-07-28)
33. FlyteHealth GA in CMS Health Technology Ecosystem (PR Newswire FDA, 2026-07-28)
34. Aqua Medical first U.S. patient for type 2 diabetes (PR Newswire FDA, 2026-07-28)
35. Lupin Diazepam Injection approval (PR Newswire FDA, 2026-07-28)
36. Nitinotes EASE IDE trial first procedures (PR Newswire FDA, 2026-07-28)
37. 2 FDA citations trouble Hengrui / Elevar (Fierce Pharma, 2026-07-28)
38. J&J $5.5B deal for ovarian cancer claims (Fierce Pharma, 2026-07-28) — johnson-and-johnson
39. Eli Lilly tops biopharma productivity ranking (Fierce Biotech, 2026-07-28) — eli-lilly
40. MapLight dives despite positive schizophrenia data (BioPharma Dive, 2026-07-26)
41. The FDA’s 505(b)(2) pathway (BioSpace, 2026-07-21)
42. The biggest career decisions (BioSpace, 2026-07-15)
43. Altimmune GLP-1 reduces heavy drinking (MedCity News, 2026-07-01)